Management & Regulatory

FDA Approves Sephience for Rare PKU Disorder Treatment
Management & Regulatory FDA Approves Sephience for Rare PKU Disorder Treatment

Imagine living with a condition where even a small bite of protein-rich food could lead to severe neurological damage, a daily reality for thousands of individuals in the U.S. diagnosed with phenylketonuria (PKU), a rare genetic metabolic disorder. Affecting approximately one in every 13,500 to

How Does Alhemo Transform Haemophilia Treatment Options?
Management & Regulatory How Does Alhemo Transform Haemophilia Treatment Options?

Hemophilia, a rare inherited bleeding disorder impacting approximately 800,000 individuals globally, has long posed significant challenges for patients and healthcare providers due to the body's impaired ability to form blood clots. For many, the struggle to manage frequent bleeding episodes with

Australia and Thailand Unite to Boost ASEAN Health Security
Management & Regulatory Australia and Thailand Unite to Boost ASEAN Health Security

In a landmark effort to strengthen health security across Southeast Asia, Australia and Thailand have embarked on a transformative partnership that promises to reshape the region’s approach to public health, bringing new hope for resilience. Announced on August 11, this collaboration brings

How Will FDA PreCheck Strengthen US Drug Supply Chains?
Management & Regulatory How Will FDA PreCheck Strengthen US Drug Supply Chains?

In a landscape where over 50% of pharmaceuticals distributed in the US are manufactured overseas, the fragility of the drug supply chain has become a pressing concern for national health security, prompting urgent action. Imagine a scenario where a global crisis disrupts access to essential

Keytruda Approved for Advanced Endometrial Cancer by NICE
Management & Regulatory Keytruda Approved for Advanced Endometrial Cancer by NICE

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into a groundbreaking advancement in cancer treatment: the recent

Becton Dickinson's Earnings Boost Signals Med Device Strength
Management & Regulatory Becton Dickinson's Earnings Boost Signals Med Device Strength

In a landscape where economic volatility often shakes investor confidence, Becton Dickinson (BDX) has emerged as a standout performer, recently revising its full-year earnings outlook upward with an adjusted diluted EPS guidance of $14.30 to $14.45, reflecting a robust 9.4% growth at the midpoint.

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later